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INTRODUCTION
Rheumatoid arthritis (RA) is a common inflammatory arthropathy which affects approximately 1% of the adult population [1] . RA is characterized by a heavy lymphocyte and plasma cell infiltrate in the synovium, synovial overgrowth; and extension of inflammatory tissue into bone; this leads to the formation of periarticular marginal erosions by osteoclasts, multinucleated cells which are specialised to carry out lacunar bone resorption. The osteoclast is a member of the mononuclear phagocyte system and is formed from CD14 + macrophage pre cursors in the presence of macrophagecolony stimulating factor (MCSF) and receptor activator for nuclear factor κB ligand (RANKL), a tumour necrosis family (TNF) superfamily member [25] . RANKL is expressed by activated fibroblasts, osteoblasts and lymphocytes which also produce osteoprotegerin (OPG), a decoy receptor for RANKL that inhibits osteoclastogenesis [6, 7] . The RANKL OPG axis is key to controlling osteoclast formation and survival. A monoclonal antibody directed against RANKL, denosumab, has been shown to increase bone mineral density and to reduce pathological bone resorption in osteoporosis and RA [811] . Several studies have shown that osteoclasts can be formed by a RANKLindependent pathway promoted by other TNF superfamily members [1217] . LIGHT (lymp hotoxinlike, exhibits inducible expression and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes) is the most potent RANKL substitute identified to date [14, 18, 19] . LIGHT (TNFSF14) is a type 2 transmembrane glycoprotein which is expressed on activated T lymphocytes, mono cytes and dendritic cells [2022] . LIGHT binds to two membranebound members of the TNFR superfamily, herpes virus entry mediator (HVEM), which is expressed by many inflammatory cells including T cells, B cells, monocytes and dendritic cells, and lymphotoxin β receptor (LTβR), which is expressed by many cell types such as fibroblasts, endothelial cells, stromal cells and monocytes but not lymphocytes [2325] . LIGHT also binds to decoy receptor 3 (DcR3), a soluble nonsignaling receptor which has been shown to modulate its function in vitro and in vivo [23, 26] . LIGHT is expressed constitutively by dendritic cells and activated T cells and is mainly found in lymphoid tissues [2022] . LIGHT has been shown to induce osteoclast formation by a RANKLindependent mechanism from monocytes [14, 19] . The role LIGHT plays in inducing pathological bone resorption in RA joints is uncertain. LIGHT levels are increased in the serum of patients with RA, and blocking the action of LIGHT has been shown to reduce the severity of murine collageninduced arthritis [14, 27] . Synovial fluid (SF) macrophages are known to differ entiate into osteoclasts in the presence of RANKL and MCSF [28] . In this study we have examined the role LIGHT plays in the pathogenesis of inflammatory joint destruction by determining whether LIGHT alone can stimulate osteoclastogenesis from SF macrophages isolated from RA joints. We have also examined whether the concentration of LIGHT is higher in RA than non inflammatory osteoarthritis (OA) SF and compared the expression of LIGHT in RA and OA synovium.
MATERIALS AND METHODS

Patients samples and reagents
SF samples were derived from six patients (four females, one male) undergoing therapeutic arthrocentesis for inflammatory joint disease. Non-inflammatory OA control SF was derived from four patients (two females, two males) undergoing unicompartmental knee replacement. All patients diagnosed with RA were seropositive for rheumatoid factor and met the ACR/EULAR diagnostic criteria for RA [29] . RA and OA synovial tissue was derived from biopsy specimens. All patients gave informed consent and the Oxford Clinical Research Ethics Com mittee approved the study.
For all tissue culture incubations, αminimum es sential medium (αMEM) (Invitrogen, United Kingdom) was supplemented with 2 mmol/L (w/v) glutamine, 10 µg/mL streptomycin, 100 IU/mL benzyl penicillin, 10% (v/v) heatinactivated fetal bovine serum (FBS). Recombinant soluble human RANKL was purchased from Peprotech Europe (London, United Kingdom); all other cytokines were purchased from R and D Systems Europe (Abingdon, United Kingdom). Primary antibodies for immunohistochemistry were purchased from Abcam (Cambridge, United Kingdom).
Isolation and culture of SF macrophages
SF macrophages were isolated from aspirates by cen trifugation at 2500 rpm for 10 min at 4 ℃; macrophages were subsequently used for osteoclastogenesis (see below) while the cellfree supernatant was frozen and stored at 80 ℃ for ELISA measurement of LIGHT levels. Following centrifugation of SF aspirates, the resultant cell pellet was resuspended αMEM/FBS and then added at 1 × 10 6 cells/well to 96 well tissue culture plates containing 5 mm dentine slices. After 2 h incubation, dentine slices were removed from the wells and washed vigorously in MEM/ FBS to remove nonadherent cells; the cell suspension was subsequently transferred to a 24well tissue culture plate containing 1 mL of MEM/FBS supplemented with various factors. As positive controls, SF macrophage cultures were maintained in the presence of 25 ng/mL MCSF plus 50 ng/mL soluble RANKL. As negative controls, cultures were maintained with MCSF alone. SF macrophages were also cultured in the presence of LIGHT (50 ng/mL) ± OPG (100 ng/mL). All SF macrophage cultures were incubated for up to 14 d, during which time the entire culture medium containing all factors was replenished every 23 d.
Characterisation of osteoclast formation and activation
Tartrate-resistant acid phosphatase: After 14 d in culture, cells were fixed in formalin and stained histochemically for tartrateresistant acid phosphatase (TRAP), an osteoclast marker, using naphthol ASBI as a substrate, in the presence of 1.0 mol/L tartrate.
F-actin ring formation:
Multiple rows of podosomes containing an Factin core are often localised in the sealing zone of osteoclasts. To detect Factin ring structure, dentine slices were fixed with 4% formaldehyde for 5 min and then permeabilised for 6 min in 0.5% Triton X100 in phosphate buffered saline (PBS) and rinsed with PBS. The cells on dentine slices were then incubated with tetramethylrhodamine isothiocyananteconjugated phalloidin (SigmaAldrich) for 30 min and observed using a fluorescence microscope (Olympus).
Lacunar resorption: Functional evidence of osteoclast formation was determined using a resorption assay system. Circular dentine slices (4 mm in diameter) were prepared from elephant tusk blocks, kindly supplied by the Customs and Excise, United Kingdom, and sterilised in absolute alcohol overnight. After 14d incubation, dentine slices on which cells had been cultured, were removed from wells, rinsed in PBS, incubated in 1.0 M ammonium hydroxide for 24 h and sonicated in distilled water for 510 min. All cellular debris was thus removed from the dentine slice permitting examination of its surface for evidence of lacunar resorption. The slices were washed in distilled water, stained with 0.5% (w/v) toludine blue in 1.0% (w/ v) boric acid pH 5.0 and examined by light microscopy. To quantify the lacunar resorption, dentine slices were photographed and the resorbed areas highlighted and measured using Adobe Photoshop CS3 and Image J (NIH, Bethesda, MD, United States).
Quantification of LIGHT levels in synovial fluid of OA and RA patients
Human LIGHT enzymelinked immunosorbent assay (ELISA) kit (R and D Systems Europe) was used to determine the concentration of soluble LIGHT in the synovial fluid derived from RA (n = 5) and OA (n = 4) patients, as per manufacturer's instructions. The upper and lower detection limits of the ELISA were 31 pg/mL and 2 ng/mL, respectively.
Immunohistochemistry of RA and non-inflammatory OA synovial tissue
Formalin-fixed, paraffin-embedded synovial biopsies of RA and OA synovium were cut (3 µm), deparaffinized with xylene and rehydrated through a series of graded alcohols. After blocking endogenous peroxidase with 0.2% (v/v) hydrogen peroxide in 80% alcohol for 30 min, antigen retrieval was performed in 500 mL 10 mmol/L Tris + 1 mol/L EDTA (BDH, United Kingdom) buffer (pH 8.5) using a microwave for 20 min. Immunohistochemistry was performed using an indirect immunoperoxidase technique with 3,3diaminobenzidine chromogen (EnVision™ + Dual Link SystemHRP, Liquid DAB + Substrate Chromogen System, Dako, United Kingdom). Sections were incubated with an antiLIGHT antibody (antihLIGHT/HVEML, R and D systems, United States) 1:5 overnight at room temperature followed by 30 min incubation with labeled polymer and 10 min in 3,3diaminobenzidene. Slides were counterstained using Mayer's haematoxylin for 3 min, blued in 2% hydrogen sodium carbonate, dehydrated, Sabokbar A et al . Role of LIGHT in RA cleared in xylene and mounted using DePeX (Surgipath, United Kingdom). All sections were examined by light microscopy.
Ethical consideration
All tissue specimens and blood samples from RA and OA patients were taken after informed consent and ethical permission was obtained for participation in the study.
Statistical analysis
The statistical review of the study was performed prior and after the study was conducted and with consultation with a biomedical statistician. Data is represented as mean ± SEM. For assessment of osteoclast resorption, the area of lacunar resorption was normalized and expressed as a percentage of RANKLinduced lacunar resorption (positive control). Statistical significance was determined by MannWhitney test or oneway ANOVA, using GraphPad Prism (Version 6.03). P value < 0.05 were considered as statistically significant. C) , confirming that LIGHT-induced osteoclast formation did not occur via the RANKL pathway. Resorption pits formed in LIGHTtreated SF macrophage cultures were smaller and more often single than in RANKLtreated cultures where most resorption pits were compound or confluent with many long resorption tracks being produced ( Figure 1B) . The overall percentage area of the dentine slice resorbed in LIGHTtreated cultures was comparable to that seen in RANKLtreated cultures ( Figure 1C ).
RESULTS
LIGHT induces RANKL-independent osteoclastogenesis from SF macrophages
LIGHT augments RANKL-induced osteoclastogenesis from SF macrophages
In 14d cultures of RA SF macrophages on dentine slices incubated with MCSF and RANKL, a significant increase in lacunar resorption was seen compared with RA SF macrophage cultures treated with RANKL alone (Figure 2 ).
LIGHT in RA and OA synovial fluid
The concentration of LIGHT was significantly elevated in the synovial fluid derived from inflammatory RA compared with noninflammatory OA joints ( Figure  3 ). The mean level of LIGHT detected in the synovial fluid of RA patients was 452.5 ± 70.5 pg/mL. This was significantly higher (P < 0.05) compared with that found in non-inflammatory OA patients (45.43 ± 19.8 pg/mL).
Expression of LIGHT in RA and OA synovium
Immunohistochemistry showed that there was little or no expression of LIGHT in OA synovium, but in RA synovium LIGHT was strongly expressed by synovial lining cells and subintimal macrophages (Figure 4 ). Endothelial cells were also weakly stained, but lymphoid cells and fibroblasts were negative.
DISCUSSION
The canonical RANKL/OPG axis is the main pathway of osteoclastogenesis and is believed to play a major role in pathological bone resorption in RA [30, 31] . RANKL expression is upregulated by inflammatory cytokines found in RA joints such as IL1, IL6, IL17 and tumor necrosis factors (TNF)α [3032] . RANKL is a member of the TNF superfamily and it has been shown that other TNF superfamily ligands can induce RANKLindependent osteoclastogenesis. In this study we show that one of these factors, LIGHT, can substitute for RANKL and induce osteoclast formation from SF macrophages derived from RA joints. LIGHTinduced osteoclast formation was not inhibited by OPG and resulted in comparable levels of lacunar resorption to that seen in RANKLtreated cultures. LIGHT also augmented RANKL mediated lacunar resorption and was found to be highly expressed in RA synovium and SF.
LIGHT is a potent RANKLindependent osteoclasto genic factor that has been shown in several studies to play a role in RA [13] . An increase in LIGHT levels has been noted in the serum of RA patients [14] . LIGHT is upregulated on Blymphocytes and monocytes in RA and it has been shown to induce the expression of proinflammatory cytokines and metalloproteinases in macrophages and synoviocytes [33, 34] . RA synovial fibroblasts express the LIGHT receptors HVEM and LTβR; LIGHT activates synovial fibroblasts, resulting in an increase in cytokines and growth factors that promote inflammation and resorption; LIGHT also induces the proliferation of RA synovial fibroblasts through LTβR [35, 36] . It has also been shown that CD14 + monocytes interact with stromal cells in RA synovium to induce the formation of TRAP + MNCs and that LIGHT enhances the generation of MNCs that release metalloproteinases including MMP9 and MMP12, both of which are found at sites of joint erosion in RA [37] . Our data indicates that LIGHT is likely to play a Sabokbar A et al . Role of LIGHT in RA significant role in pathological bone resorption in RA. SF macrophages, like monocytes, are CD14 + cells that are capable of differentiating into osteoclasts [28] . These cells are present in increased numbers in RA compared with OA joints and joint fluid, as are other inflammatory cells that are known to express LIGHT. This accords with our finding that the concentration of LIGHT is increased in RA compared with noninflammatory OA joint fluid. There was little expression of LIGHT in OA synovium whereas it was strongly expressed in RA synovium mainly in synoviocytes and subintimal macrophages. The combination of an increased number of CD14 + mo nonuclear phagocyte osteoclast precursors and high levels of LIGHT in the SF provides the conditions for LIGHTinduced osteoclastogenesis to exist in inflamed RA joints.
In keeping with previous studies [14] , we found that LIGHTinduced osteoclast differentiation from RA SF macrophages occurred in the absence of RANKL. LIGHT induced osteoclastogenesis was not inhibited by the RANKL inhibitor OPG and was comparable to that seen in RANKLtreated SF macrophage cultures in terms of formation of TRAP + MNC and lacunar resorption. We also found that LIGHT significantly augmented osteoclast formation in the presence of RANKL, in keeping with the findings of Ishida et al [37] who noted that LIGHT promotes resorption in RA. In keeping with this conclusion, Fava et al [27] showed that prophylactic treatment with the LIGHT pathway inhibitor protein LTβRIg blocks induction of collageninduced arthritis in mice and adjuvant arthritis in Lewis rats. There is likely to be a complex interplay between RANKLindependent and RANKLdependent mechanisms in inflamed RA joints. The role that T cells and synovial fibroblasts play in RANKL/LIGHTinduced osteoclast formation is likely to be key given that these cells are known to express both RANKL and LIGHT. It has been shown the LIGHT contributes to the survival and activation of synovial fibroblasts in RA, resulting in pannus formation which promotes the generation of metalloproteinases, inflammatory cytokines and adhesion molecules [3336] . RANKLindependent mechanisms of osteoclast formation induced by TNF superfamily members have been shown to play a role in the osteolysis associated with several neoplastic and nonneoplastic diseases of bone and joint, including giant cell tumour of bone, Ewing sarcoma, metastatic breast carcinoma, melanoma and myeloma [13, 38] . LIGHT is the most potent TNF superfamily member identified to date that induces RA NKLindependent osteoclast formation. LIGHT is likely to represent a potentially useful therapeutic target in RA as inhibiting its action would not only reduce synovial inflammation but also LIGHT and RANKLmediated lacunar resorption, resulting in more complete healing of marginal erosions and preservation of periarticular bone in RA. A number of studies have shown that Denosumab, a fully humanised antibody that specifically binds RANKL can be used to treat joint erosions and periarticular bone loss in RA [3943] . Denosumab, however, unlike LIGHT, has no effect on joint inflammation [8, 9, 39] . It is well recognized that in the treatment of giant cell tumour of bone, withdrawal of Denosumab results in the reemergence of osteoclasts with consequent osteolysis and regrowth of the tumour [44, 45] . The use of Denosumab to treat bone loss in RA is also likely to encounter this problem as fibroblastic stromal cells that express RANKL would persist in the inflammatory environment. Following this therapy targeting LIGHT would therefore be useful in this context as it would not only inhibit the proliferation and activation of RANKL-expressing synovial fibroblasts but also reduce LIGHT and RANKLmediated bone resorption.
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COMMENTS
Background
Rheumatoid arthritis (RA) is characterized by a heavy lymphocyte and plasma cell infiltrate in the synovium, which leads to the formation of periarticular marginal erosions by specialized multinucleated cells, osteoclasts, which carry out lacunar bone resorption. Osteoclast formation and activation is controlled by a receptor-activator nuclear factor kappa-B ligand (RANKL)-OPG axis, in RA as well as RANKL-independent pathway. One of the RANKL-independent mediators of osteoclast activation is an activated T-cell product, known as LIGHT which is also known to be expressed by dendritic cells.
Research frontiers
Serum levels of LIGHT are increased in RA patients and blocking the action of LIGHT has been shown to reduce the severity of murine collagen-induced arthritis. It is uncertain whether LIGHT is involved in activation of RA synovial fluid macrophages to osteoclasts.
Innovations and breakthroughs
This is the first study evaluating the role of LIGHT in osteoclastogenesis of RA patients as well as demonstrating the increased LIGHT levels in synovial fluid of RA as compared to osteoarthritic patients.
Applications
The elevated levels of LIGHT in synovial fluid of RA patients and the ability of LIGHT to induce RANKL-mediated osteoclast activation indicate that this protein plays a significant role in pathogenesis of RA, which had not been previously reported.
Terminology
LIGHT is an abbreviation for lymphotoxin-like, exhibits inducible expression and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes) is the most potent RANKL (receptor activator for nuclear factor κB ligand) substitute identified to date, both of which are tumour necrosis family superfamily members.
Peer-review
The authors demonstrated the possible role of LIGHT in stimulating osteoclast resorption in synovial fluid macrophages. This type of activity was enhanced in combination of RANKL and macrophage-colony stimulating factor. Overall, the paper is logical and well-organized. 
